Usher Syndrome Gene Therapy Study Begins in Oregon
March 6, 2012 – The first-ever gene therapy for Usher syndrome, a devastating condition that causes both blindness and deafness, has moved into a Phase I/IIa clinical trial at the Foundation-funded Casey Eye Institute, Oregon Health & Science University (OHSU). The research team, led by Dr. Richard Weleber, is preparing to treat its first patient.
Developed by Oxford BioMedica, a biopharmaceutical company in the U.K. and a Foundation partner, the UshStat® treatment is designed to halt vision loss in people affected with Usher syndrome type 1B, which is caused by defects in the MY07A gene. Based on results in lab studies, researchers believe a single UshStat treatment may last several years, perhaps a lifetime.
“We are delighted to see Oxford’s innovative gene therapy for Usher 1B move into human studies. It is a critical milestone in our campaign to overcome vision loss from a particularly challenging condition,” says Dr. Stephen Rose, the Foundation’s chief research officer. “UshStat is great news for the Usher syndrome community, because there are virtually no vision-related treatment options available for any form of the disease. While the treatment is for Usher 1B, success in the trial will open the door for using gene therapy to treat other forms of Usher syndrome.”
UshStat is the third Oxford BioMedica gene therapy to move into a clinical trial. StarGen™, the company’s gene therapy for Stargardt disease, is in a Phase I/IIa human study at OHSU and the Centre Hospitalier Nationale d'Ophthalmologie des Quinze-Vingts in Paris. The company’s RetinoStat®, a gene therapy for wet age-related macular degeneration, is in a Phase I clinical study at Wilmer Eye Institute at Johns Hopkins Hospital in Baltimore, Maryland.
Oxford says that the first six patients in the RetinoStat trial and the first four in the StarGen study are doing well. No safety issues or adverse events have occurred. The company will report additional results for RetinoStat in the first half of 2012 and for StarGen in the second half of the year.
The two-year UshStat study will enroll 18 patients affected by Usher syndrome type 1B. One eye of each patient will be injected with the therapy. The trial will evaluate the treatment’s safety as well as changes in retinal function of the treated eye versus the untreated eye.
To participate in the UshStat trial, patients will need to be 18 years or older and have had a genetic test confirming the diagnosis of Usher syndrome type 1B. For more information on trial participation, visit the clinical trials page of the Foundation’s website, which requires registration.
The UshStat treatment is contained in a tiny drop of liquid that is injected beneath the retina and absorbed by retinal cells in a matter of hours. The treatment uses Oxford’s LentiVector® gene delivery technology, a re-engineered virus, to enable healthy copies of the MYO7A gene to penetrate the cells. A key benefit of the LentiVector technology is its ability to deliver large genes, like MYO7A, which other viral systems are not able to deliver.
Usher syndrome is the leading cause of combined deafness and blindness in the world. It affects approximately 45,000 people in the United States. There are three primary types of Usher syndrome, designated by numerals, and 12 subtypes, designated by letters.
“We are excited about the potential for our powerful gene therapy technology to save and restore vision, and we are grateful to the Foundation Fighting Blindness for playing a critical role in moving it out of the lab and into clinical trials. It has been an outstanding partnership,” says Stuart Naylor, Ph.D., chief scientific officer, Oxford BioMedica.作者: 勇敢的老虎 时间: 2012-3-7 08:41
UshStat是第三牛津BioMedica基因疗法进入临床试验的移动。 StarGen™，该公司为Stargardt病的基因治疗，是在一个阶段我/第IIa在OHSU和中心医院NATIONALE D'Ophthalmologie DES Quinze-Vingts在巴黎的人体试验。该公司的RetinoStat®，为湿性年龄相关性黄斑变性的基因治疗，是我在马里兰州巴尔的摩市约翰斯·霍普金斯医院Wilmer眼科研究所临床研究阶段。
“我们很高兴我们强大的基因治疗技术的潜力，以保存和恢复视力，我们感谢基金会战斗失明的发挥了它在移动实验室，进入临床试验的关键作用。它一直是一个优秀的合作伙伴关系，说：“司徒勒，博士，首席科学官，牛津BioMedica。
Google 翻译（企业版）：译者工具包网站翻译器全球商机洞察
关闭即时翻译关于 Google 翻译移动隐私权政策帮助发送反馈作者: 福娃晶晶 时间: 2012-3-7 09:21
